CLDX vs. BYRN

Last updated Apr 1, 2026

Compare and contrast key facts about Celldex Therapeutics, Inc. (CLDX) and Byrna Technologies Inc. (BYRN).

Performance

CLDX vs. BYRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Celldex Therapeutics, Inc. (CLDX) and Byrna Technologies Inc. (BYRN). The values are adjusted to include any dividend payments, if applicable.

CLDX vs. BYRN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CLDX Celldex Therapeutics, Inc.	16.79%	7.48%	-36.28%	-11.02%	15.35%	120.55%	685.65%	-24.88%	-93.03%	-19.77%
BYRN Byrna Technologies Inc.	-45.32%	-41.72%	350.86%	-18.49%	-41.27%	-7.93%	663.16%	26.67%	7.14%	-30.00%

Fundamentals

EPS CLDX : -$3.38 BYRN : $0.40
PS Ratio CLDX : 810.15 BYRN : 1.87
Total Revenue (TTM) CLDX : $2.60M BYRN : $118.12M
Gross Profit (TTM) CLDX : $1.78M BYRN : $71.47M
EBITDA (TTM) CLDX : -$252.86M BYRN : $13.46M

Returns By Period

In the year-to-date period, CLDX achieves a 16.79% return, which is significantly higher than BYRN's -45.32% return. Over the past 10 years, CLDX has underperformed BYRN with an annualized return of -6.06%, while BYRN has yielded a comparatively higher 33.78% annualized return.

CLDX

• 1D: 7.60%
• 1M: 5.42%
• YTD: 16.79%
• 6M: 22.61%
• 1Y: 74.77%
• 3Y*: -4.11%
• 5Y*: 6.82%
• 10Y*: -6.06%

BYRN

• 1D: 3.73%
• 1M: -28.17%
• YTD: -45.32%
• 6M: -58.57%
• 1Y: -45.49%
• 3Y*: 6.55%
• 5Y*: -6.29%
• 10Y*: 33.78%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CLDX vs. BYRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CLDX

CLDX Risk / Return Rank: 79
CLDX Sharpe Ratio Rank: 79
CLDX Sortino Ratio Rank: 80
CLDX Omega Ratio Rank: 74
CLDX Calmar Ratio Rank: 82
CLDX Martin Ratio Rank: 82

BYRN

BYRN Risk / Return Rank: 18
BYRN Sharpe Ratio Rank: 14
BYRN Sortino Ratio Rank: 15
BYRN Omega Ratio Rank: 17
BYRN Calmar Ratio Rank: 20
BYRN Martin Ratio Rank: 21

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CLDX vs. BYRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Celldex Therapeutics, Inc. (CLDX) and Byrna Technologies Inc. (BYRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CLDX	BYRN	Difference
Sharpe ratio Return per unit of total volatility	1.20	-0.65	+1.85
Sortino ratio Return per unit of downside risk	2.06	-0.76	+2.81
Omega ratio Gain probability vs. loss probability	1.24	0.91	+0.33
Calmar ratio Return relative to maximum drawdown	2.44	-0.63	+3.07
Martin ratio Return relative to average drawdown	6.48	-1.12	+7.60
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CLDX vs. BYRN - Sharpe Ratio Comparison

The current CLDX Sharpe Ratio is 1.20, which is higher than the BYRN Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of CLDX and BYRN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CLDX	BYRN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.20	-0.65	+1.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.11	-0.09	+0.20
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.08	0.20	-0.28
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.05	-0.13

Correlation

The correlation between CLDX and BYRN is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CLDX vs. BYRN - Dividend Comparison

Neither CLDX nor BYRN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CLDX vs. BYRN - Drawdown Comparison

The maximum CLDX drawdown since its inception was -99.73%, which is greater than BYRN's maximum drawdown of -92.51%. Use the drawdown chart below to compare losses from any high point for CLDX and BYRN.

Drawdown Indicators

	CLDX	BYRN	Difference
Max Drawdown Largest peak-to-trough decline	-99.73%	-92.51%	-7.22%
Max Drawdown (1Y) Largest decline over 1 year	-24.23%	-73.78%	+49.55%
Max Drawdown (5Y) Largest decline over 5 years	-73.11%	-92.51%	+19.40%
Max Drawdown (10Y) Largest decline over 10 years	-97.93%	-92.51%	-5.42%
Current Drawdown Current decline from peak	-94.41%	-73.15%	-21.26%
Average Drawdown Average peak-to-trough decline	-77.86%	-51.99%	-25.87%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.14%	41.24%	-32.10%

Volatility

CLDX vs. BYRN - Volatility Comparison

The current volatility for Celldex Therapeutics, Inc. (CLDX) is 14.93%, while Byrna Technologies Inc. (BYRN) has a volatility of 16.55%. This indicates that CLDX experiences smaller price fluctuations and is considered to be less risky than BYRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CLDX	BYRN	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.93%	16.55%	-1.62%
Volatility (6M) Calculated over the trailing 6-month period	40.48%	44.57%	-4.09%
Volatility (1Y) Calculated over the trailing 1-year period	63.12%	70.18%	-7.06%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.05%	72.38%	-12.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.61%	168.26%	-89.65%

Financials